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Background
Bone Morphogenetic Proteins (BMPs) are multifunc-
tional, secreted cytokines belonging to the TGF-b super-
family. These proteins act as a disulfide-linked
homodimer, being potent regulators of bone and cartilage
formation and repair, cell proliferation in embryonic
development and adult bone homeostasis. BMPs are pro-
mising molecules in periodontal regeneration to treat
physiopathological bone loss and non-union fractures and
in oral surgery, and to accelerate and increase osseointe-
gration. BMPs are dimeric molecules displaying sites for
N- and O-glycosylation, which increases the stability and
half-life of the protein in the body, in addition to deter-
mining the specificity of receptor coupling. BMP-2
induces cartilage and bone formation. BMP4 has also
been shown to play a role in triggering osteoblastic differ-
entiation of mesenchymal stem cells, through activation
of osteoblastic related genes. In order to ensure proper
glycosylation and conformational folding and to prevent
immunogenicity, we elected a mammalian cell expression
system to produce these BMPs aiming at bone regenera-
tion, stem cell proliferation and differentiation and their
application in human and veterinary cell therapy.
Methods
BMPs 2 and 4 cDNAs were amplified from an in-house
constructed cDNA Bank and cloned into the pGEM®-T-
Easy vector. E. coli transformants were screened by
colony PCR. Upon DNA sequencing, the BMP 2 and 4
inserts were transferred to a lentiviral expression vector.
HEK293 cells were co-transfected with a lentiviral plas-
mid containing both BMP 2 or 4 and eGFP cDNAs, by
co-transfection, at a 40:1 ratio, with a Hygror vector for
clone selection. Cell clones were selected using 100 ug/
mL hygromicin. Several cell clones were characterized
and highest overproducing ones were selected for each
protein. BMPs expression was analyzed by qRT-PCR,
Western blotting, and in vitro biological activity by alka-
line phosphatase activity in C2C12 cells during 7 days.
Recombinant proteins were purified using heparin affi-
nity chromatography.
Results and conclusions
Upon cell cloning, most of the cells present in the
selected clones were positive for GFP, indicating that a
high transfection efficiency was achieved. BMPs 2 and 4
were continuously secreted to the medium even after
120h of serum starvation. Purification of rhBMP2 and 4
from the conditioned medium resulted in more than 90%
purity. The rhBMPs 2 and 4 bound to the resin were
eluted in 450mM NaCl buffer, with a single dimeric
30-37 kDa band being observed in the eluates. In vitro
assays showed that the purified rhBMPs 2 and 4 dis-
played high osteogenic activity. The in vivo osteogenic
bioactivity analysis of the purified proteins by ectopic
bone formation using Rowett rats is underway. Glycosy-
lation analysis using exoglicosidase digestion and struc-
tural analysis of the purified proteins is underway. The
use of these biopharmaceuticals in bone Tissue
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Engineering is likely to allow accelerated recovery to both
human patients and animals.
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